Biotech catalyst, news and analysis PDUFA tracker
Tickers reports and analysis
NEAT is clearly positive, Quince can be re-rated as a near-launch rare-disease company with credible billion-dollar potential and strategic appeal. If NEAT fails or is weak, equity value could be severely impaired given the single-asset focus, limited cash and EIB debt.
Focus: FDA approval of Zycubo (copper histidinate, ex CUTX-101) as first treatment for Menkes disease in children – monetisation of milestones, royalties and potential PRV for Fortress/Cyprium.
Today is about one thing: uncertainty around the FDA decision timing/outcome for the FILSPARI FSGS sNDA. The company explicitly highlighted FDA information requests right before the target date.
Focus: multi-year low 9-figure Satellite Services contract with the Swedish Armed Forces – third sovereign-space deal in 12 months, >$500M combined.
Tenax Therapeutics (TENX) – Deep Dive / Analisi Approfondita (Jan 2023 – Oggi) Tenax Therapeutics (TENX) – Deep Dive / Analisi Approfondita (Jan 2023 – Oggi) Full deep dive on TENX: financials, pipeline, catalysts, shareholder structure, insider activity, dilution, analyst…
Precision oncology company built around synthetic lethality, with darovasertib in uveal melanoma and a broad pipeline (MAT2A, PRMT5, PARG, ADCs) backed by more than 1.1 billion dollars in cash and a guided runway into 2030.
Focus: FDA PDUFA for KRESLADI™ (LAD-I) on March 28, 2026 – gene therapy, rare pediatric disease.
Yesterday’s report framed ATRA around a PDUFA-window setup, with the assumption that the 2025 CRL was primarily a CMC/GMP story and that the ALLELE trial remained acceptable as the pivotal efficacy dataset. Today that premise is broken: the FDA has issued a second Complete Response Letter (CRL) for tabelecleucel/tab-cel in EBV+ PTLD.
Biotech catalysts, small-cap rotation, space & defence names already on the Merlintrader radar, Trump factor, geopolitics (Ukraine, Red Sea, Venezuela, Greenland) and J.P. Morgan Healthcare Conference 2026.
As of January 10, 2026, Sana Biotechnology (NASDAQ: SANA) stands as a clinical-stage pioneer focused on the development of engineered cells as a new modality of medicine. Founded on the belief that cell therapy will follow small molecules and biologics as the "third pillar" of therapeutics, Sana has built a platform to address the two primary bottlenecks of the industry: Immune Evasion and Scalable Manufacturing.
Madrigal (MDGL) is a commercial-stage biopharma focused on metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). Its lead product, Rezdiffra (resmetirom), received FDA accelerated approval on March 14, 2024 as the first treatment for adults with noncirrhotic MASH with moderate to advanced fibrosis (F2–F3), to be used with diet and exercise.
CorMedix Inc. has crossed a line that many small biotechs never reach. It is no longer a binary, pre-revenue story waiting for a single FDA decision. With DefenCath approved, the Melinta acquisition closed and several hundred million dollars of revenue on the board, CRMD now behaves like a small-cap specialty pharma focused on preventing and treating serious infections linked to vascular access.
Summit Therapeutics Inc. (NASDAQ: SMMT) has effectively transformed itself into a single-asset, late-stage oncology company centered on ivonescimab (SMT112), a PD-1 × VEGF bispecific antibody licensed from Akeso in January 2023 (FY2024 PR). Ivonescimab is already approved in China (Akeso) and is now in a broad, global Phase III program led by Summit in NSCLC and colorectal cancer.
Revolution Medicines, Inc. (Nasdaq: RVMD) enters the 44th Annual J.P. Morgan Healthcare Conference as a late-stage, pre-commercial oncology company focused on RAS(ON) inhibitors. The company’s FY24 results release (link) positions RVMD as “a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers,” with a deep pipeline led by daraxonrasib, elironrasib and zoldonrasib.
Ocugen, Inc. (Nasdaq: OCGN) is a clinical-stage biotechnology company focused on gene therapies for blindness diseases and related ophthalmic biologics. Its core asset base is a “modifier gene therapy” platform built around nuclear hormone receptors (NHRs) designed to reset dysfunctional retinal gene networks rather than replace single mutated genes. The three flagship programs are OCU400 for retinitis pigmentosa (RP), OCU410 for geographic atrophy (GA, late-stage dry age-related macular degeneration) and OCU410ST for Stargardt disease, each targeting sizeable unmet-need populations in inherited and multifactorial retinal disease.
Cellectar Biosciences (Nasdaq: CLRB) is a late-stage clinical radiopharmaceutical company built around a proprietary phospholipid drug conjugate (PDC) platform. Its lead asset, iopofosine I 131, delivers radioactive iodine-131 directly to tumor cell membranes; the most advanced program is in relapsed/refractory Waldenström macroglobulinemia (WM) after BTK inhibitor therapy, supported by the pivotal CLOVER-WaM Phase 2 data described in the company’s Form 10-K 2024 (Business section).
On 9 January 2026, Aquestive Therapeutics announced that the US FDA had identified “deficiencies” in the NDA for Anaphylm (dibutepinephrine sublingual film). These deficiencies currently preclude discussions of labeling and post-marketing commitments.
A factual deep dive on where SAVA really stands after shutting down Alzheimer’s, pivoting to TSC-related epilepsy, facing a full FDA clinical hold, settling a $31.25M class action and attracting heavy call-option interest and insider buying.
HSV-1 gene therapy platform moves from skin to lung: robust CFTR expression in CF lungs, repeat dosing on deck, and JPM 2026 as the launchpad for a mutation-agnostic CF strategy.
SIDU, ASTS, LUNR, ONDS and PL are not just “hot tickers”. Their satellites, landers, drones and imaging constellations are becoming building blocks of a Western answer to China’s dual-use space programs, Russia’s drone war and a world where infrastructure and data are contested every single day.
